A Peptide-Centric Quantitative Proteomics Dataset for the Phenotypic Assessment of Alzheimer’s Disease

Alzheimer’s disease (AD) is a looming public health disaster with limited interventions. Progress in therapeutic development requires a more detailed understanding of molecular pathogenesis. Most data for AD pathogenesis in humans is from standard neuropathologic assessments, e.g., neuritic plaques and neurofibrillary tangles or biochemical measurement of a limited number of analytes related to neuropathologic features, e.g., amyloid-β peptides and hyperphosphorylated tau. Standard neuropathologic evaluation is highly valuable as it provides assessment of diseases that afflict an individual brain, but it also is limited in its ability to investigate molecular pathogenesis. Modern mass spectrometry-based proteomics enable quantitative insight into the protein phenotype in brains with AD neuropathology. Careful selection of specimens enabled us to investigate protein signatures specific to autosomal dominant AD dementia (ADD), sporadic ADD with minimal comorbidities, individuals without dementia who had high histopathologic burden of AD, and cognitively normal individuals with no or minimal AD histopathologic burden. All data are deposited in the ProteomeXchange proteomic data repositories (ID: PXD034525).